Therefore, NIBAN1 might regulate FAK signaling activation to promote GEM resistance in bladder cancer, and targeting NIBAN1/FAK signaling could potentially sensitize bladder cancer cells to GEM chemotherapy. This evidence concerns the gene PTK2 and urinary bladder cancer.